Mary Beth Nierengarten

CMS rewrite of medicaid Managed Care Rule addresses criticisms

01/28/2019

For nearly 2 years, since CMS’ final rule was released, states, health plans, and providers have operated under its statutes and discovered difficulties. A rewrite offers a chance to correct those issues.

For nearly 2 years, since CMS’...

01/28/2019

First Report Managed Care

Collaborative Initiatives Aim to Improve Care for Patients with Multiple Myeloma

06/09/2015

Mary Beth Nierengarten ;

Changes in the evolving healthcare environment are focusing on greater cooperation between providers and payers to improve quality of care while reducing cost.

Changes in the evolving...

06/09/2015

First Report Managed Care

Glucocorticoids in Older and Poorer Patients

02/14/2013

Mary Beth Nierengarten ;

Washington, DC—Despite current guidelines that recommend the use of disease-modifying antirheumatic drugs (DMARDs) for treatment of active rheumatoid arthritis (RA), many people are still treated with glucocorticoids alone for long periods of...

Washington, DC—Despite current...

02/14/2013

First Report Managed Care

Department

Better Prevention of Clostridium Difficile Infections Needed

06/19/2012

Mary Beth Nierengarten ;

Most of the substantial increase in Clostridium difficile infections (CDIs) over the past decade in the United States is related to healthcare exposures that may be prevented by reducing unnecessary antibiotic use and interrupting...

Most of the substantial increase...

06/19/2012

First Report Managed Care

News Connection

Bapineuzumab Shows No Clinical Benefit for Mild-to-Moderate AD

03/18/2014

Mary Beth Nierengarten ;

Results of 2 phase 3, multicenter, randomized, double-blind trials show no clinical benefit of bapineuzumab to treat patients with mild-to-moderate Alzheimer’s disease (AD) [N Engl J Med. 2014;370:322-33]. The study did find, however, that...

Results of 2 phase 3,...

03/18/2014

First Report Managed Care

News

Budget Analysis of Addition of Riociguat for PAH and CTEPH

03/16/2015

Mary Beth Nierengarten ;

Results of a budgetary impact model study showed that the addition of riociguat to treat patients with PAH or CTEPH offers US health plans an additional treatment for these conditions that is safe, effective, and associated with minimal...

Results of a budgetary impact...

03/16/2015

First Report Managed Care

News

Abuse-Deterrent Opioids: High Costs and Vague Outcomes Hurt Uptake

07/07/2017

Mary Beth Nierengarten ;

With all stakeholders looking for a solution to the opioid misuse epidemic, some have pointed to abuse-deterrent formulations as a possible solution; however, their high costs and lack of sufficient real-world efficacy have prevented...

With all stakeholders looking...

07/07/2017

First Report Managed Care

Economic Benefit Suggested with Abatacept for RA

02/19/2014

Mary Beth Nierengarten ;

San Diego—Use of abatacept as first- or second-line treatment for patients with moderate-to-severe rheumatoid arthritis (RA) may have an economic benefit over other biologic disease-modifying antirheumatic drugs (DMARDs) agents, as...

San Diego—Use of abatacept as...

02/19/2014

First Report Managed Care

Stroke Severity and Hospital Performance Ranking

09/14/2012

Mary Beth Nierengarten ;

Results of a study that used a risk model to compare hospital performance in care for acute ischemic stroke [JAMA. 2012;308(3):257-264] showed that adding stroke severity to the risk model was associated with a considerable improvement in the...

Results of a study that used a...

09/14/2012

First Report Managed Care

Feature

Omalizumab Improves Asthma Control in Inner-City Youth

06/21/2011

Mary Beth Nierengarten ;

Results of a randomized, double-blind, placebo-controlled, multicenter trial [N Engl J Med. 2011;364(11):1005-1015] show that the addition of omalizumab to guidelines-based therapy improved asthma control, reduced the need for other...

Results of a randomized,...

06/21/2011

First Report Managed Care